Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Harrow Health Inc (HROW) is a leading developer of ophthalmic pharmaceuticals and non-intravenous sedation therapies, addressing critical needs in eyecare and procedural medicine. This dedicated news hub provides investors and healthcare professionals with timely access to official announcements and objective updates about the company's progress.
Our curated collection features earnings reports, regulatory milestones, and product development updates, offering a comprehensive view of HROW's strategic direction. Users will find essential information on FDA approvals, clinical trial results, and partnership announcements that shape the company's position in the pharmaceutical sector.
Key content categories include financial disclosures, research breakthroughs, and manufacturing updates related to compounded medications and sedation therapeutics. All materials are sourced from verified channels to ensure accuracy and relevance for decision-makers.
Bookmark this page for streamlined access to HROW's latest developments. Check back regularly for authoritative updates on innovations in ocular surface disease treatments and non-IV sedation solutions that demonstrate the company's commitment to advancing patient care.
Harrow Health (NASDAQ: HROW) announced the acquisition of U.S. commercialization rights for four FDA-approved ophthalmic medications from Novartis for $14 million. The products include IOPIDINE®, MAXITROL®, and MOXEZA®, which will enhance Harrow's portfolio in the ophthalmic surgical and acute care markets. This acquisition positions Harrow as a unique provider of both branded products and compounded formulations in the U.S. market, leveraging its ImprimisRx platform for distribution.
Harrow Health, Inc. (Nasdaq: HROW) has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective December 20, 2021. This inclusion is a recognition of the company's performance among biotechnology and pharmaceutical securities. CEO Mark L. Baum expressed pride in this milestone, viewing it as validation of the team's efforts to create value for stakeholders. Harrow Health focuses on ophthalmic healthcare, operating ImprimisRx and Visionology, and has interests in other pharmaceuticals. The company aims to provide innovative and affordable eye care solutions.
Harrow Health reports record revenues of $18.7 million for Q3 2021, marking a 30% increase from $14.4 million in the same period last year. The company maintains a gross margin of 74% and achieved commissions from DEXYCU® sales of $900,000. Harrow acquired two FDA drug candidates, AMP-100 and MAQ-100, aiming to enhance its product offerings. Cash and cash equivalents stood at $57.9 million as of September 30, 2021. CEO Mark L. Baum emphasized strong revenue growth, despite challenges posed by COVID-19.
Harrow Health, Inc. (NASDAQ: HROW) will release its third-quarter financial results for 2021 on
Harrow Health, Inc. (NASDAQ: HROW) announced a $13.5 million senior secured loan to Melt Pharmaceuticals, Inc. to support the Phase 2 study of its lead drug candidate MELT-300, aimed at providing a non-opioid solution for sedation during cataract surgery. Melt plans to dose the first patient in
Harrow Health (NASDAQ: HROW), an ophthalmic-focused healthcare company, announced that Mark L. Baum, CEO, and Andrew Boll, CFO, will participate in two virtual investor conferences. The first is the H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021, where a pre-recorded presentation will be available on their website from 7:00 a.m. ET. The second is the Lake Street Capital Market’s 5th Annual Best Ideas Growth Conference on September 15, 2021, where management will hold one-on-one meetings with investors.
Harrow Health, Inc. (NASDAQ: HROW) reported record financial results for Q2 and H1 ended June 30, 2021, marking its best quarter ever with significant growth in revenues, cash flow from operations, and Adjusted EBITDA. The company raised $75 million in unsecured capital, which is being utilized for strategic initiatives, including the acquisition of AMP-100, an ophthalmic anesthetic drug candidate, with an FDA application expected soon. Harrow anticipates a strong second half of 2021, aimed at enhancing product diversity and operational performance.
Harrow Health (NASDAQ: HROW) has entered an agreement with Sintetica, S.A. to acquire marketing and supply rights for AMP-100, an innovative ophthalmic surgical drug candidate for ocular surface anesthesia. This acquisition targets a market with over 10 million procedures annually in the U.S. AMP-100's safety and efficacy are backed by a comprehensive clinical program and a successful Phase 3 study. Sintetica plans to submit a New Drug Application to the FDA in late 2021. Harrow aims to leverage its commercial platform to maximize AMP-100's market potential.
Harrow Health, Inc. (NASDAQ: HROW) announced the release of its financial results for Q2 and six months ended June 30, 2021, scheduled for August 10, 2021, post-market. The company will share its second-quarter letter to stockholders on its website. A conference call and live webcast will follow at 4:45 PM ET to discuss results and provide a business update. Harrow Health is focused on ophthalmology, operating ImprimisRx and Visionology, and holds equity positions in Eton Pharmaceuticals, Surface Ophthalmics, and Melt Pharmaceuticals.
FAQ
What is the current stock price of Harrow Health (HROW)?
What is the market cap of Harrow Health (HROW)?
